Intermittent vismodegib dosing to treat multiple basal-cell carcinomas
Mené sur 229 patients atteints d'un carcinome basocellulaire multiple, cet essai randomisé de phase II évalue l'efficacité, du point de vue de la réduction du nombre de cas cliniques à la semaine 73, et la toxicité de deux dosages intermittents de vismodégib, un inhibiteur de la voie Hedgehog
Many basal-cell carcinomas can be treated effectively by uncomplicated surgical excision.1 Longstanding tumours, which are often neglected or maltreated, might become inoperable. Targeted treatment with Smoothened homologue (SMO) inhibitors, such as vismodegib and sonidegib, has shown part or complete clearance.2,3 In patients with advanced basal-cell carcinoma, however, 1 year of vismodegib treatment was associated with complete response in only 34%, and resistance seemed to be a serious problem.
The Lancet Oncology , commentaire, 2016